Host an Educational Program
Satellite Symposia provide your organization with a unique opportunity to host educational programs before or after DDW scientific sessions, often offering CME credit to participants. A limited number of symposia will be permitted so be sure to reserve yours today. Please note that DDW Council policy prohibits Satellite Symposia during scheduled scientific sessions.
Application and Deadlines
There is no application deadline; however, slots are assigned based on receipt of full payment. We can accept applications until all the slots are full.
View Recorded Symposia
Symposia 2023 are available to view on demand through our virtual platform.
Guidelines
A limited number of satellite symposia will be permitted at DDW 2024. This number is driven by hotel meeting space availability, which may vary in each city. Please keep in mind DDW hosts over 300+ In-Conjunction With meetings in addition to symposia only at our contracted hotel locations. The DDW Council prohibits symposia during scheduled scientific sessions. Symposia, or any portion of them, including registration and question-and-answer sessions, may only be held prior to 7:45 a.m. or after 6 p.m. during the designated timeslots. This policy will be strictly enforced, and any violations will result in loss of priority points earned for DDW 2024 if the symposium is hosted or supported by a current showcase supporter. If the symposium is not affiliated with a current industry supporter, DDW will determine the appropriate action, which is not limited to expulsion from participating in future DDW events.
- Space will be assigned by DDW on a first come, first served basis, based on hotel availability and when full payment is received. Your symposium will not be placed until DDW has received full payment, regardless of your application date. Meeting space placement will begin in December 2023. You will receive communication once placement has been made.
- Symposia can be placed in any of the official DDW hotels based on meeting space availability. Altering your meeting specifications can result in movement of your symposia to another hotel location. Meeting space reservations are not exclusive to symposia.
- Meeting space locations can be subject to food and beverage minimums, space rental, audio visual and equipment rental fees that is the responsibility of the symposia host. The symposia fee paid to DDW does not include these additional fees.
- Space assignments are final and may not be switches unless done so by DDW.
- Symposia dates are May 17–21, 2024. Only morning and evening slots are available. Morning symposia must end by 7:45 a.m., including question-and-answer periods. Evening symposia cannot start before 6 p.m., including the registration process as well as any food and beverage period. The duration of the symposium is up to the sponsoring company to arrange.
- Dates and times submitted on the application are just preferences. DDW will confirm your final date and time, once full payment has been received, based on availability.
- All confirmed dates and times are final and may not be switched unless done so by DDW.
Available Dates and Times:
| Dates | Morning Slots | Evening Slots |
|---|---|---|
| Fri, May 17 | N/A | Call for information |
| Sat, May 18 | 2 | 6 |
| Sun, May 19 | 2 | 6 |
| Mon, May 20 | 2 | 6 |
| Tues, May 21 | 2 | N/A |
The fee for one morning slot is $50,000, and the fee for one evening slot is $55,000. Please see the list below for additional information.
| Morning symposium | $50,000 |
| Evening symposium | $55,000 |
| Two morning symposia | $75,000 |
| Two evening symposia | $85,000 |
| Morning and evening symposia | $80,000 |
| Morning symposium (non-exhibitor) | $57,500 |
| Evening symposium (non-exhibitor) | $62,500 |
- DDW will assign appropriate meeting space, day, time and provide the appropriate hotel contacts.
- DDW will provide one complimentary pre-registrant mailing list for use to promote the symposium. Subsequent lists can be purchased and are discounted 50% from the regular fee. Pre-registration list will be exported from the DDW registration database. DDW is not responsible for list clean up or integrity of this list. List will be supplied by request.
- DDW will send one combined email blast to attendees about two weeks prior to the convention.
- DDW will provide two complimentary attendee badges (per symposium) to non-ticketed DDW scientific sessions.. Complimentary attendee name badges are due by Wednesday, April 3, 2024.
- DDW will list your Symposium on the DDW website, mobile app and online platform prior to the convention.
- If you wish to have an online component for your Satellite Symposium, it is your responsibility to coordinate. Supporters will be responsible for providing the link to the online symposium or recording. DDW will place the link on the online platform and on DDW.org through Friday, Aug. 30, 2024. Link to your online meeting room, website or recording will be due to DDW by Friday, April 26, 2024. More information will be provided once a contract is submitted.
For marketing opportunities for Satellite Symposia, please email your industry contact below.
| TESSA AYALA Account Manager Industry Sales and Operations |
Pre-Meeting
- DDW reserves the right to review all symposium applications and promotional materials and to reject topics, formats or materials deemed inappropriate.
- Program content must be relevant to digestive health or GI practice.
- Approval from DDW does not constitute an endorsement of the program or its contents by DDW or its partnering societies.
Printed and Published Materials
- All industry sponsors/supporters must be listed on all printed and published materials.
- All printed and published materials must bear the following information: Sponsored by…, Supported by…, and coordinated by…
- All advertisements, promotions or invitations for the symposium must bear the following statement: “This program is not affiliated with Digestive Disease Week®.” This statement must appear on the cover/front page of any copy using at least a 12-pt. font size.
- The DDW logo and the Digestive Disease Week® (or DDW®) name may not be used in any promotions, advertisements, meeting materials or correspondence related to the program.
Payment Terms
All DDW Satellite Symposia and Marketing Opportunities will be billed at 100% upon selection and execution of the application and sponsorship contracts. Payment is due no later than 30 days from the date of order. Failure to make full payment by this date will result in the item being placed back into inventory for another party to purchase and Satellite Symposia organizers will incur cancellation fees for the Satellite Symposia fee (see below).
All payments are non-refundable after Saturday, Feb. 3, 2024.
If an order is placed after Tuesday, Feb. 13, 2024, payment will be due upon reservation.
DDW reserves the right to not fulfill any unpaid Marketing Opportunities.
Space will be assigned only after full payment has been received based on availability at that time. Meeting space placement will begin in December 2023. You will receive communication once placement has been made.
Cancellation Fee
Notification of satellite symposium must be in writing. Any supporter canceling a satellite symposium will be charged a fee based on the following schedule:
- On or before Tuesday, Feb. 27, 2024: 50% of total fee is due, regardless of whether the slot is re-sold.
- After Tuesday, Feb. 27, 2024: 100% of total fee is due, regardless of whether the slot is re-sold.
Satellite Symposium cancellations will result in automatic cancellation of any marketing opportunities and registered staff secured for the satellite symposium. No refunds will be provided for these other opportunities.
FAQs
Approximately 13,000+ attendees for both in-person and the online platform.
DDW does not guarantee attendance. Attendance heavily depends on your topic; however, date and time may have some impact based on conflicting priorities. Attendance is primarily driven by pre-show marketing efforts and tactics deployed by sponsoring organizations. Based on historical data, a.m. symposia can average anywhere between 150-350 attendees, and p.m. symposia average anywhere from 200-500 attendees. DDW does not track audience demographics at symposia.
Yes, but we will not coordinate any of the details and you would be required to do so yourself. We also will not provide a virtual platform for it.
No. You must provide or independently obtain the CME or CE certification for your activity.
No.
DDW is not involved in the content of the actual event, but we must review and approve all copy for invitations and flyers sent to DDW attendees.
DDW allows partners to post their presentations online if the presentation does not make mention of DDW. Presentations must be hosted by the education partner. DDW will post a link to the education partner’s website on the Satellite Symposia Schedule page for attendees to view post show. Links will be posted until Friday, Aug. 30, 2024.
Yes, however it is the sponsor’s responsibility to collect any contact information during the symposium and to acquire all the permissions to contact each attendee. DDW cannot provide attendee contact information. All promotional materials for live streaming presentations or hosting presentations online must follow DDW’s rules and regulations and must be reviewed and approved by DDW prior to release.
Saturday, May 18, 2024
| 6 p.m. | Test Your Ability to Manage Ulcerative Colitis: An Interactive Case-Based Challenge |
| Supported by: Lilly Provided by: Medscape | |
| 6–7:30 p.m. | |
| Embassy Suites by Hilton Room: Capital BCD | |
| The treatment landscape for ulcerative colitis (UC) is rapidly evolving. Novel pharmacologic agents with different and unique mechanisms of action are significantly advancing the management of UC. In this unique and interactive “Test and Teach”-style symposium, attendees will answer a series of clinical, case-based questions posed by expert faculty on the management of UC, after which the faculty will discuss the answers and present supporting evidence. This format allows learners to see how their responses compare with those of their peers and receive expert feedback on their clinical decision-making in real time. Thus, participants will be educated on the latest data on new and emerging advanced UC therapies, as well as the latest guidance and expert opinion on UC management, which they can apply in their practices. To learn more and register, please visit us online. | |
| CRC Blood-Based Screening Era | |
| Supported by: Guardant Health | |
| 6–9:30 p.m. | |
| Marriott Marquis Room: China Town | |
| An educational session for gastroenterologists to better understand ShieldTM , a blood-based CRC screening test, and how it will fit in with the current modalites of testing to improve patient screening rates. |
Sunday, May 19, 2024
| 6:15 a.m. | Assembling the Puzzle of Eosinophilic Esophagitis: Where Novel Therapies May Fit Into Treatment Plans |
| Supported by: Regeneron Pharmaceuticals, Inc and Sanofi Provided by: Answers in CME | |
| 6:15–7:45 a.m. | |
| Marriott Marquis Room: Marquis Ballroom Salons 1-4 (Meeting Level 2) | |
| Join us for a lively discussion led by renowned experts Dr. Evan S. Dellon and Dr. Amanda Muir, featuring patient perspectives from Matt Katz. This one-hour, accredited event promises a comprehensive exploration of the latest advancements in the treatment of EoE. Learn from the experts about the opportunities and limitations of different treatment modalities of EoE, treatment considerations for adult vs. pediatric patients, and how biologic therapies may fit into treatment plans. Learn from a patient about the real-life impact of EoE and why timely recognition of this disease is critical. Register here. | |
| 6 p.m. | Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH? |
| Supported by: Novo Nordisk Provided by: PVI, PeerView Institute for Medical Education | |
| Capital Hilton Room: Presential Ballroom (Second Floor) | |
| 6–7:30 p.m. | |
| This interactive event will explore the evolving understanding of MASLD and MASH, including challenges in the management of these conditions, new and emerging therapeutic agents, and practical guidance on how to effectively and safely incorporate noninvasive monitoring and novel therapies into patient care. Experts will square off against artificial intelligence by posing case scenarios and clinical practice questions on making optimal management decisions. To learn more about the symposium, the CME credit offered, and to pre-register, visit us here. | |
| The IBD Game Show: Challenging Learners on Advanced Therapies in IBD | |
| Supported by: AbbVie Provided by: Medscape | |
| 6–7:30 p.m. | |
| Capital Hilton Room: Federal AB | |
| The treatment landscape for inflammatory bowel disease (IBD) is evolving rapidly. Novel pharmacologic agents with different mechanisms of action are advancing the management of both ulcerative colitis and Crohn’s disease. Clinicians need education to stay abreast of the latest developments in IBD treatment, including positioning of new agents in treatment plans, efficacy and safety data, setting treatment goals, monitoring response, and adjusting treatment in patients who relapse. Join us for a fun, educational, and interactive Jeopardy-style symposium on IBD. Compete against your peers as you answer challenging questions on IBD management led by a professional host. Learn from expert faculty who will discuss the latest clinical evidence and nuances in clinical care in IBD that you can apply in your practices to improve patient outcomes. To learn more and register, visit us here. | |
| What’s New in the Treatment of Gastroesophageal Reflux Disease and Erosive Esophagitis: Spring Meeting Updates | |
| Supported by: Phantom Pharmaceuticals Provided by: Medscape | |
| 6–7:30 p.m. | |
| Embassy Suites by Hilton Room: Capital A | |
| The prevalence of gastroesophageal reflux disease (GERD) in the United States continues to increase, and up to half of patients with reflux symptoms do not get adequate relief from empiric therapy with proton pump inhibitors, the mainstay of GERD treatment. In this live, interactive townhall, expert faculty will discuss the latest evidence and data regarding the diagnosis and management of GERD and erosive esophagitis (EE), including new acid suppressive medications. Real-world patient cases will help learners contextualize clinical information on GERD evaluation and management to apply in their practices. To learn more and register please visit: http://www.medscape.org/symposium/gerd-updates | |
| Exclusive From Washington D.C.: Illuminating Ulcerative Colitis Management in 2024 | |
| Supported by: Lilly Provided by: Lilly | |
| 6–7:30 p.m. | |
| Embassy Suites by Hilton Room: Capital BCD | |
| Explore and identify unmet needs in the management and treatment of ulcerative colitis (UC) through patient case discussions. | |
| One Size Does Not Fit All: Improving Patient Care in IBS-C | |
| Supported by: Ardelyx Provided by: Focus Medical Communications | |
| 6–8 p.m. | |
| Marriot Marquis Room: Marquis Salon 5 (Meeting Level 2) | |
| One Size Does Not Fit All: Improving Patient Care in IBS-C will provide education focused on advances in the management of IBS-C, understanding of the mechanism of disease, and impact of quality of life for people living with IBS-C. Register here. Jointly provided by the Medical Education Resources and the Gi Health Foundation. Supported by an educational grant from Ardelyx, Inc. | |
| 6:30 p.m. | Livestream: Visualizing the Future: Advances in IL-23-Targeted Therapies in the Treatment of IBD |
| Supported by: Janssen Provided by: CME Outfitters, Inc. | |
| 6:30–8 p.m. | |
| Capital Hilton | |
| Interleukin (IL)-23 has been identified as a main driver of inflammation in inflammatory bowel disease (IBD) and has been identified as a target for highly effective advanced therapies. While all agents in the anti-IL-23 class of monoclonal antibodies (mABs) neutralize IL-23 by binding the Fab fragment to the P19 domain, the differences in Fc fragment structure may impact potency and clinical efficacy. Fc structure differences have been shown to impact binding of different agents to CD64 positive myelocytes, a main source of IL-23 in active IBD. In this CME Outfitters livestream symposium, expert faculty will review the role of the IL-23/Th-17 pathway in the pathogenesis of IBD and utilize animated 3-D models to illustrate differences in agents in the anti-IL-23 class that may have potential therapeutic implications. Learners will be guided through an evaluation of the potential clinical implications of CD64 receptor binding by anti-IL-23 mAbs in IBD treatment, as well as the clinical evidence supporting the benefits of these IBD treatment features. Join the livestream here. |
Monday, May 20, 2024
| 6:15 a.m. | Livestream: Shedding Light on Bowel Urgency: Presenting the Latest Data and Initiating Conversations in Crohn’s Disease Management |
| Supported by: Lilly USA Provided by: CME Outfitters, LLC | |
| 6:15–7:30 a.m. | |
| Capital Hilton | |
| Patients with Crohn’s disease (CD) frequently experience bowel urgency, a symptom resulting in rushing to the bathroom and sometimes causing loss of bowel control. The symptom of bowel urgency dramatically impacts patient quality of life (QoL), and can lead to depression, social isolation, disruption with work, interference with relationships and sexual intimacy, sleep disruptions, and fatigue. Bowel urgency is more commonly associated with ulcerative colitis, leading many gastroenterologists to forget to assess for this symptom in patients with CD or to only assess for it in patients with disease in the colon region. However, over 70% of patients with CD experience bowel urgency and it is reported as a common and disruptive symptom alongside pain and fatigue. Join the livestream here. | |
| Clearing the Esophageal Buildup: Can Timely Diagnosis and Novel Pharmacotherapies Pave the Way in Eosinophilic Esophagitis? | |
| Supported by: Takeda Pharmaceuticals USA, Inc. Provided by: Answers in CME | |
| 6:15–7:45 a.m. | |
| Marriott Marquis Room: Marquis Ballroom Salons 1-4 (Meeting Level 2) | |
| Join our faculty—two gastroenterology experts—for this 1-hour, accredited breakfast symposium about recent advances in the diagnosis and management of eosinophilic esophagitis (EoE). Dr. Ikuo Hirano and Dr. David A. Katzka will discuss practical considerations, such as: What are the latest diagnostic recommendations? How to tailor the selection of nonpharmacologic and pharmacologic interventions? Which patients may benefit from novel swallowed topical corticosteroids? What are some of the short-term vs long-term considerations for managing a patient? And more… Register here. | |
| 6 p.m. | Breaking Barriers: Challenges and Needs in Fibrostenosing Crohn’s Disease |
| Supported by: Agomab Therapeutics | |
| 6–7 p.m. | |
| Mariott Marquis Room: Marquis Ballroom Salons 7-10 (Meeting Level 2) | |
| Can Small Changes in Practice Make a Difference to Your Patients With Crohn’s Disease? | |
| Supported by: Lilly | |
| 6–7:30 p.m. | |
| Embassy Suites by Hilton Room: Capital BCD | |
| Learning objectives include: Apply a holistic approach to treat-to-target in Crohn’s disease; Employ practical strategies to address unmet patient needs; and Integrate symposium learnings through an interactive panel discussion. | |
| Unmasking IgG4-Related Disease in the GI Arena: Awareness, Diagnosis, and Navigating Treatment | |
| Supported by: Horizon Therapeutics USA, Inc. | |
| 6–8:00 p.m. | |
| Marriott Marquis Room: Marquis Ballroom Salon 6 (Meeting Level 2) | |
| This CE dinner symposium aims to improve awareness for gastrointestinal manifestations of immunoglobulin G4-related disease (IgG4-RD), a disease that is underrecognized and often misdiagnosed, through a discussion on its differential diagnosis as well as current and emerging management options. Register here. Join the livestream here. | |
| Fine-Tuning the Care of Patients With Moderate-to-Severe Crohn’s Disease Using Novel Targeted Therapies | |
| Supported by: AbbVie Provided by: Answers in CME | |
| 6–7:30 p.m. | |
| Marriott Marquis Room: Marquis Ballroom Salons 1-4 (Meeting Level 2) | |
| Join our faculty experts for this 1-hour accredited event about recently approved JAK inhibitors and IL-23 inhibitors for the treatment of moderate-to-severe Crohn’s disease. Targeted approaches have emerged in recent years as effective treatment options for other inflammatory diseases, which further complicates the crowded Crohn’s treatment landscape. Dr. Russell D. Cohen and Dr. Uma Mahadevan will focus on the clinical impact of these new therapies, including the latest efficacy and safety data, and evidence-based strategies to personalize treatments to help clinicians meet the challenges of the evolving treatment landscape. Faculty will draw on their own experiences to provide practical case-based insights on using these newly approved treatments to optimize the management of this debilitating disease. Register here. | |
| Overlapping Symptoms in Gastroenterology: Can You Diagnose These Patients? | |
| Supported by: Academy for Continued Healthcare Learning | |
| 6–7:45 p.m. | |
| Marriott Marquis Room: Marquis Salon 5 (Meeting Level 2) | |
| How do you differentiate among functional gastrointestinal disorders with overlapping symptoms? Test your skills on employing optimal diagnostic tools and criteria to see if you get to the right diagnosis. | |
| The Inflammatory Tissue Microenvironment in IBD: The Role and Clinical Relevance of CD64 | |
| Supported by: Johnson&Johnson | |
| 6–8 p.m. | |
| Capital Hilton Room: Federal AB |
Related Opportunities
Product Theater
Product Theaters are turnkey, 45-minute marketing presentations about your company’s products or services.
In-Conjunction With Meetings
ICWs are meetings and events arranged by exhibitors, third-party planners, educational institutions or other non-profit organizations.
Industry Supporter Prospectus
The prospectus provides details you need to know to reserve your space at DDW 2024.
